{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":40,"n_cols":5,"rows_kept":40,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[10,2,10,3],[11,2,11,3],[20,2,20,3],[20,4,20,5],[21,2,21,3],[21,4,21,5],[22,2,22,3],[23,2,23,3],[25,2,25,3],[26,2,26,3],[27,2,27,3],[29,2,29,3],[33,2,33,3],[34,2,34,3],[37,2,37,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISA996395381203316"]
[null,null,"Titolo",null,"By the King [[electronic resource] ] : A proclamation for restraint of killing, dressing, and eating flesh in Lent, or on fish dayes, appointed by the law, to be hereafter strictly obserued by all sorts of people.  Whereas, for the benefit and commoditie of this our realme of England, as well in the maintenance of our Nauie and shipping ."]
[null,null,"Pubbl/distr/stampa",null,"Imprinted at London, : by Bonham Norton and Iohn Bill, Printers to the Kings most Excellent Maiestie., M. DC. XXIIII. [1624]"]
[null,null,"Descrizione fisica",null,"[3] leaves : coat of arms"]
[null,null,"Soggetti",null,"Lent - England"]
[{"$nulls":4},"Fasts and feasts - England"]
[{"$nulls":4},"Meat industry and trade - England"]
[{"$nulls":4},"Broadsides17th century.England"]
[{"$nulls":4},"Proclamations17th century.England"]
[{"$nulls":4},"Great Britain History James I, 1603-1625 Sources Early works to 1800"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Title taken from caption and first lines of text."]
[{"$nulls":4},"Imprint taken from colophon."]
[{"$nulls":4},"\"Giuen at our court at Newmarket the seauenth day of February, in the two and twentieth yeere of our reigne of Great Britaine, France, and Ireland.\" --Leaf [3]."]
[{"$nulls":4},"Sheet 1 has last indented line to right of init. beginning: 'dayes' and line 9 begins: 'kinde'.  Cf.  STC (2nd ed.)."]
[{"$nulls":4},"Royal coat of arms with 'I R' at top, tailpiece, initial."]
[{"$nulls":4},"Reproduction of original in: Queen's College (University of Oxford). Library."]
[null,null,null,"Sommario/riassunto","eebo-0119"]
[null,"2.","Record Nr.",null,"UNINA9910647778203321"]
[null,null,"Titolo",null,"Ethics and Clinical Neuroinnovation : Fundamentals, Stakeholders, Case Studies, and Emerging Issues / / edited by Laura Weiss Roberts"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023"]
[null,null,"ISBN",null,"9783031143397"]
[{"$nulls":4},"9783031143380"]
[null,null,"Edizione",null,"[1st ed. 2023.]"]
[null,null,"Descrizione fisica",null,"1 online resource (352 pages)"]
[null,null,"Disciplina",null,"616.8"]
[{"$nulls":4},"174.2968"]
[null,null,"Soggetti",null,"Neurosciences"]
[{"$nulls":4},"Neuropsychology"]
[{"$nulls":4},"Neurology"]
[{"$nulls":4},"Neuroscience"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Section 1: Fundamentals: the imperative for novel clinical therapeutics for mental disorders -- Chapter 1: The case for neuroinnovation: Health burdens associated with psychiatric, addiction-related, and co-occurring disorders -- Chapter 02: Neuroinnovation in medicine: History and future -- Chapter 03: Clinical neuroinnovation: Ethical frameworks and emerging issues -- Chapter 04: Changing contexts of neuroinnovation: Societal considerations -- Chapter 05: Changing contexts of neuroinnovation: Societal considerations -- Chapter 06: The NIH’s BRAIN2025 agenda: Attention to related ethical considerations -- Section 2: Special Topics in Clinical Neuroinnovation -- Chapter 07: In the surgical suite: Neurosurgery and neuroinnovation, and the ethics of neurostimulation for severe obesity -- Chapter 08: In the midst of uncertainty: Neuroinnovation at the edge of consciousness -- Chapter 09: On the edges: The ethics of human studies with psychedelic substances -- Chapter 10: In the courts: Emerging neuroscience technologies used for forensic purposes: ethical and legal implications -- Chapter 11: Into the wild: A comment on neuroethics startups - Moving from lab to society -- Section 3: Neuroethics and Innovation: Inquiry informed by the Roberts Valence Model -- Chapter 12: Introduction to our project: Understanding ethically-salient "]
[{"$nulls":4},"perspectives of diverse societal stakeholders in innovative neuroscience research on mental disorders -- Chapter 13: Qualitative phase: Codebook development -- Chapter 14: Qualitative findings: Diverse stakeholder perspectives on ethical considerations in innovative neuroscience research involving human volunteers -- Chapter 15: Qualitative findings: A focus on professional stakeholder perspectives on the environments and challenges of innovative neuroscience research -- Chapter 16: Qualitative findings: A focus on professional stakeholder perspectives on additional issues in research and clinical innovation in the brain -- Chapter 17: Pilot quantitative phase: Amazon MTurk as a novel approach to stakeholder-based neuroethics survey research."]
[null,null,null,"Sommario/riassunto","New ways of understanding the brain – its nature, its capacities, its function, and its dysfunction – hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances. An introduction to the imperative to develop new treatments for devastating brain disorders and the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists and neuroethicists outline the clinical and the ethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly written contributions on novel qualitative and quantitative data from stakeholders in the field, including neuroscientist-clinicians, people living with mental illness and/or addictions, and oversight/policy stakeholders. Concise, anticipatory, and centered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law."]